June 23, 2026 — Today, GenBio AI announced its collaboration with NVIDIA to accelerate the development of virtual-cell world models: AI systems designed to simulate human cellular behavior across biological modalities and scales.
What Is a Virtual-Cell World Model?
To discover and develop new medical treatments, researchers must understand how living human cells respond to a wide variety of changes: what happens throughout the system when a gene is switched off, a drug is introduced, or a disease disrupts normal function? With conventional methods, this is extraordinarily difficult. Of every 10,000 compounds entering the drug development pipeline, only one on average reaches the clinic, because human biology is incredibly complex and existing tools capture only fragments of it.
A virtual cell world model (VCWM) is a simulation engine built to solve this problem. Using world model architecture, biologists will be able to predict, simulate, and ultimately program cellular processes across all biological scales, molecular and cellular. This enables deeper understanding of disease mechanisms, faster testing of therapeutic hypotheses, and better evaluation of candidate interventions in a digital laboratory before any physical experiment is run.
GenBio AI’s central thesis is that the virtual cell is not simply another predictive model. A true virtual cell is a computational system that can reason over biological state, intervention and outcome, shifting biology from isolated prediction tasks toward comprehensive simulation. The gap between that vision and today’s reality is stark. Building one good cell model requires researchers to spend countless hours manually designing architectures, tuning dozens of settings, fixing problems, and testing ideas. This process can take months of expert iteration with no guarantee of a useful result. To close that gap, the GenBio AI team built a new tool: VCHarness.
What is GenBio AI’s VCHarness?
VCHarness is GenBio AI’s autonomous agentic system for constructing virtual-cells. Rather than relying on human researchers to design each model by hand, VCHarness does the work autonomously: it proposes a candidate model, writes the code, runs the experiment, measures the results, learns from what worked and what didn’t, and tries again – all in a continuous loop.
The system combines a library of pre-trained biological foundation models (covering the DNA, protein, RNA, and cellular levels ) with AI coding agents, structured search, evaluation, memory, and distributed execution to generate, test, debug, and refine candidate virtual cell components. Together, these allow VCHarness to efficiently search over complete executable modeling workflows and learn from experimental results, going from biological question to validated model candidate in a fraction of the time previously required.
In tests predicting how human cells respond to CRISPR gene edits (a benchmark task for virtual-cell research), VCHarness discovered models that outperformed expert-designed baselines in days rather than months. Critically, it didn’t just tune existing designs – it discovered novel combinations of biological AI components.
How Will GenBio AI and NVIDIA Work Together?
GenBio AI is integrating NVIDIA BioNeMo, NVIDIA Megatron, NVIDIA NIM microservices, and the NVIDIA BioNeMo Agent Toolkit to further accelerate the construction and deployment of virtual-cell systems. GenBio AI plans to leverage NVIDIA’s life-sciences AI infrastructure, model-development tooling, and agent-ready biology components as part of a broader stack for scaling autonomous model construction, and high-throughput virtual cell experimentation.
“GenBio AI is building toward a functional world model of the virtual cell: an AI system that can simulate how cells respond to a wide variety of genetic, chemical, and environmental interventions,” said GenBio AI President and Chief Scientist Eric Xing. “VCHarness is our agentic engine for building these systems. NVIDIA BioNeMo and the BioNeMo Agent Toolkit provide crucial infrastructure and capabilities that allow us to scale this work faster, while our internal teams continue to develop the core models, algorithms, and autonomous systems that define our virtual-cell platform.”
By combining GenBio AI’s virtual-cell world-model architecture and autonomous model-building technology with NVIDIA’s accelerated computing and BioNeMo ecosystem, the companies aim to make agentic life-sciences workflows more scalable, reproducible, and useful for real-world discovery.
About GenBio AI
GenBio AI is building AI systems for biology, with a focus on world models of the virtual cell. The company develops biological foundation models, autonomous agentic systems, and multimodal simulation frameworks designed to predict, simulate, and program cellular behavior across scales.
